Le contenu de Patient est révisé par notre équipe de contenu clinique, conformément à la norme du NHS pour la création de contenu sur la santé.
Kate Thorpe
Kate leads the Society as Executive Director, overseeing its strategy, governance and growth. She is responsible for ensuring the organisation delivers its mission to support clinicians, advance education, and strengthen standards in the prescribing of cannabis-based medicines. Kate works closely with the committee and external partners to drive collaboration and influence policy. She also manages key relationships with stakeholders, sponsors and regulators, ensuring the Society remains the trusted voice for medical cannabis in the UK.
Kate’s web presence
A récemment contribué à :
Recent Freedom of Information (FOI) data from the NHS Business Services Authority has prompted sensational headlines about a sharp rise in private prescriptions for medical cannabis in the UK. On the surface, the figures look dramatic. Between 2023 and 2024, prescriptions more than doubled, rising from around 283,000 to 659,000. But these numbers need context. Without it, they risk being misunderstood. This article explains what the data does and does not show, why prescribing has increased, and what this means for patients, clinicians and the NHS.
